Related Experiment Videos
Familial hypercholesterolaemia in a Belgian community
1Centre de Recherche Médicale de Jolimont and Department of Internal Medicine, H pital de Jolimont, Haine Saint-Paul, Belgium. descaoli@skypro.be
Insights
Familial hypercholesterolaemia (FH) is a genetic disorder causing high LDL-cholesterol and early heart disease. This study explores FH diagnosis and molecular spectrum in Belgium, aiming for practical clinical criteria.
Area of Science:
- Cardiovascular Genetics
- Clinical Lipidology
- Genetic Epidemiology
Background:
- Familial hypercholesterolaemia (FH) is a genetic disorder characterized by defective low-density lipoprotein (LDL) removal, leading to elevated LDL-cholesterol and premature cardiovascular disease.
- Despite being well-understood, FH presents diagnostic challenges, necessitating differentiation from other hypercholesterolaemia causes due to significant clinical and therapeutic implications.
- Early and aggressive LDL-cholesterol lowering and cascade screening are crucial for FH management due to its dominant inheritance and severe cardiovascular risk.
Purpose of the Study:
- To investigate the prevalence, morbidity, and genetic characterization of FH in Belgium.
- To understand the molecular spectrum of FH by screening LDL-receptor and Apo B mutations in suspected individuals.
- To establish specific and feasible diagnostic criteria for routine clinical practice based on accumulated clinical data from genetically ascertained FH patients.
Main Methods:
- Large-scale genetic screening of LDL-receptor and Apo B genes in individuals suspected of having FH.
- Accumulation and analysis of extensive clinical data from patients with genetically confirmed FH.
- Development and validation of diagnostic criteria for FH in a routine medical setting.
Main Results:
- Initiated understanding of the molecular spectrum of FH in Belgium through genetic screening.
- Collected substantial clinical data from a cohort of genetically ascertained FH patients.
- Progress made towards establishing practical diagnostic criteria for FH.
Conclusions:
- FH diagnosis remains a clinical challenge, impacting timely and aggressive cardiovascular risk management.
- Genetic characterization and clinical data analysis are essential for improving FH diagnosis and understanding its spectrum in specific populations.
- The development of sensible, feasible diagnostic criteria is crucial for effective routine clinical practice and patient management.
Abstract:
Familial hypercholesterolaemia (FH) is a genetic disease in which low-density lipoproteins are defectively removed from plasma as a result of mutations that impair the function either of the LDL receptor or of the apolipoprotein B. The consequences are an elevated concentration of LDL-cholesterol and the early occurrence of cardiovascular diseases. Although FH is well understood, it remains a diagnostic challenge for the clinician. Differentiating FH from other causes of hypercholesterolaemia has, however, important clinical and therapeutic implications: FH being associated with early and severe cardiovascular risk, the plasma LDL-cholesterol must be lowered as drastically and as early as possible; because FH is a dominantly inherited disorder, family members need to be screened and counseled. Prevalence, morbidity and genetic characterization of FH have never been explored in our country. Through our experience of large-scale screening of LDL-receptor and Apo B amongst suspected individuals, we are beginning to understand the molecular spectrum of FH in Belgium. Furthermore, using the large collection of clinical data accumulated amongst patients with genetically ascertained FH, we have attempted to establish specific and sensible diagnostic criteria useful and feasible in routine medical practice.